Literature DB >> 2477165

Intralymphatic infusion of interferon in patients with lymph nodal metastases from melanoma of the lower limbs.

E Sulis1, C Floris, C Massidda.   

Abstract

In five patients with regional lymph nodal metastases from malignant melanoma of the lower limbs, intralymphatic infusion of interferon caused a complete remission in one patient and a partial remission in two others. The remaining two patients, in whom the massive neoplastic infiltration had obstructed the inflow of the drug in the tumoural seat, were unresponsive. Since the efficacy of interferon seems to be dose-dependent, intralymphatic infusion causes the accumulation of massive quantities of the drug in the tumoural seat, thus favouring its antiproliferative action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477165     DOI: 10.1007/bf00257450

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

Review 1.  Evaluation of routes of administration of interferon in cancer: a review and a proposal.

Authors:  V Bocci
Journal:  Cancer Drug Deliv       Date:  1984

Review 2.  Immunopharmacology. Immunomodulation and immunotherapy.

Authors:  J W Hadden
Journal:  JAMA       Date:  1987-11-27       Impact factor: 56.272

3.  Regional intralymphatic infusion (ILI) of irradiated tumor cells with evidence of distant effects.

Authors:  G J Juillard; P J Boyer; C H Yamashiro; H D Snow; T H Weisenburger; T McCarthy; R J Miller
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

4.  Administration of antigen by intralymphatic route in the rat I. Humoral response to soluble antigens. (delta). Preliminary report.

Authors:  E Sulis; M Busilacchi; R Turno; A Monni; A Chessa; P Zizi; P Pani; P E Manconi
Journal:  Boll Ist Sieroter Milan       Date:  1976-07-31

5.  Endolymphatic radiotherapy in malignant lymphomas. A clinical evaluation of 285 patients.

Authors:  G Bonadonna; S Chiappa; R Musumeci; C Uslenghi
Journal:  Cancer       Date:  1968-10       Impact factor: 6.860

Review 6.  Progress toward therapeutic application of interferons, 1979-1983.

Authors:  E C Borden
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.